{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T05:54:56Z","timestamp":1722405296905},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00105-021-04868-4","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T15:02:53Z","timestamp":1627657373000},"page":"1071-1078","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapie der atopischen Dermatitis mit Dupilumab"],"prefix":"10.1007","volume":"72","author":[{"given":"Sigbert","family":"Jahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"F\u00f6hr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Diamanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"4868_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjd.18958","volume":"183","author":"S Abraham","year":"2020","unstructured":"Abraham\u00a0S, Haufe\u00a0E, Harder\u00a0I et\u00a0al (2020) The TREATgermany study group. Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany. Br J Dermatol 183:382\u2013384","journal-title":"Br J Dermatol"},{"key":"4868_CR2","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1365-2222.2003.01803.x","volume":"33","author":"CA Akdis","year":"2003","unstructured":"Akdis\u00a0CA, Akdis\u00a0M (2003) Immunologic differences between intrinsic and extrinsic types of atopic dermatitis. Clin Exp Allergy 33:1618\u20131621","journal-title":"Clin Exp Allergy"},{"key":"4868_CR3","first-page":"488","volume":"17","author":"N Ascodi","year":"2019","unstructured":"Ascodi\u00a0N, Thuraum\u00a0S, Seegr\u00e4ber\u00a0M et al (2019) Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges 17:488\u2013492","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"4868_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck\u00a0LA, Thaci\u00a0D, Deleuran et al (2020) Dupilumab provides favorable safety and sustained efficacy for up to 3\u00a0years in an open-label study of adults with moderate-severe atopic dernatitis. Am J Clin Dermatol 21:567\u2013577","journal-title":"Am J Clin Dermatol"},{"key":"4868_CR5","first-page":"1150","volume":"17","author":"T Bieber","year":"2019","unstructured":"Bieber\u00a0T (2019) Novel therapies based on the pathophysiology of atopic dermatitis. J\u00a0Dtsch Dermatol Ges 17:1150\u20131161","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"4868_CR6","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt\u00a0A, deBruin-Weller\u00a0M, Gooderham\u00a0M et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids. (LIBERTY AD CHRONOS): a\u00a01-Year randomized , double-blinded, placebo-controlled phase 3 trial. Lancet 389:2287\u20132303","journal-title":"Lancet"},{"key":"4868_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/ACI.0000000000000378","volume":"17","author":"R Campana","year":"2017","unstructured":"Campana\u00a0R, Dzore\u00a0S, Mittermann\u00a0I et\u00a0al (2017) Molecular aspects of allergens in atopic dermatitis. Curr Opin Allergy Clin Immunol 17:269\u2013277","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4868_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaad.2013.10.036","volume":"70","author":"JJ Chen","year":"2014","unstructured":"Chen\u00a0JJ, Applebaum\u00a0DS, Sun\u00a0GS et\u00a0al (2014) Atopic keratokonjunctivitis: a review. J\u00a0Am Acad Dermatol 70:569\u2013575","journal-title":"J Am Acad Dermatol"},{"key":"4868_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/BF01324251","volume":"46","author":"R Doll","year":"2001","unstructured":"Doll\u00a0R (2001) Cohort studies. History of the method. II. Retrospective cohort studies. Sozial Pr\u00e4ventivmed 46:152\u2013160","journal-title":"Sozial Pr\u00e4ventivmed"},{"key":"4868_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","volume":"156","author":"AM Drucker","year":"2020","unstructured":"Drucker\u00a0AM, Ellis\u00a0AG, Bohdanowicz\u00a0M et\u00a0al (2020) Systemic immunomodulatory treatments for patients with atopic dermatitis. JAMA Dermatol 156:659\u2013667","journal-title":"JAMA Dermatol"},{"key":"4868_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","volume":"20","author":"LF Eichenfield","year":"2019","unstructured":"Eichenfield\u00a0LF, Bieber\u00a0T, Beck\u00a0LA (2019) Infections in dupilumab clinical trials in atopic dermatitis: a\u00a0comprehensive pooled analysis. Am J Clin Dermatol 20:443\u2013456","journal-title":"Am J Clin Dermatol"},{"key":"4868_CR12","first-page":"1280","volume":"18","author":"U Gieler","year":"2020","unstructured":"Gieler\u00a0U, Gieler\u00a0T, Milena\u00a0E et\u00a0al (2020) Skin and psychosomatics\u2014psychodermatology today. J\u00a0Dtsch Dermatol Ges 18:1280\u20131298","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"4868_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(02)07500-1","volume":"359","author":"DA Grimes","year":"2002","unstructured":"Grimes\u00a0DA, Schulz\u00a0KF (2002) Cohort studies: Marching towards outcomes. Lancet 359:341\u2013345","journal-title":"Lancet"},{"key":"4868_CR14","first-page":"433","volume":"17","author":"W Grobe","year":"2019","unstructured":"Grobe\u00a0W, Bieber\u00a0T, Novak\u00a0N (2019) Pathophysiology of atopic dermatitis. J\u00a0Dtsch Dermatol Ges 17:433\u2013440","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"4868_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.4103\/0019-5154.91832","volume":"56","author":"S Handa","year":"2011","unstructured":"Handa\u00a0S, De\u00a0D, Mahajan\u00a0R (2011) Airborne contact dermatitis\u2014current persepctives in etiopathogenesis and management. Indian J\u00a0Dermatol 56:700\u2013706","journal-title":"Indian J Dermatol"},{"key":"4868_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1055\/a-1209-0885","volume":"46","author":"S Jahn","year":"2020","unstructured":"Jahn\u00a0S, F\u00f6hr\u00a0J, Herbst\u00a0M (2020) Immunomodulators (Biologicals) in the treatment of patients with chronic dermatoses in the dermatological practice. Akt Dermatol 46:425\u2013433","journal-title":"Akt Dermatol"},{"key":"4868_CR17","first-page":"1","volume":"5","author":"U Jappe","year":"2021","unstructured":"Jappe\u00a0U, Beckert\u00a0H, Bergmann\u00a0K\u2011C et al (2021) Biologics for atopic diseases: Indication, side effect management, and new developments. Allergolselect 5:1\u201325","journal-title":"Allergolselect"},{"key":"4868_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","volume":"9","author":"IS Juntilla","year":"2018","unstructured":"Juntilla\u00a0IS (2018) Tuning the cytokine responses: an update on Interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol 9:888","journal-title":"Front Immunol"},{"key":"4868_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/1744666X.2017.1292134","volume":"13","author":"M Kraft","year":"2017","unstructured":"Kraft\u00a0M, Worm\u00a0M (2017) Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol 13:301\u2013310","journal-title":"Expert Rev Clin Immunol"},{"key":"4868_CR20","first-page":"795","volume":"18","author":"MP Sch\u00f6n","year":"2020","unstructured":"Sch\u00f6n\u00a0MP, Berking\u00a0C, Biedermann\u00a0T et al (2020) COVID-19 und Immunregulation \u2013 von grundlegenden und translationalen zu klinischen Implikationen. J Dtsch Dermatol Ges 18:795\u2013809","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"4868_CR21","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson\u00a0EL, Bieber\u00a0T, Guttman-Yassky\u00a0E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N\u00a0Engl J Med 375:2335\u20132348","journal-title":"N Engl J Med"},{"key":"4868_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","volume":"132","author":"M Suarez-Farinas","year":"2013","unstructured":"Suarez-Farinas\u00a0M, Dhingra\u00a0N, Gittler\u00a0J et al (2013) Intrinsic atopic dermatitis (AD) shows similar Th2 and higher Th17 immune activation compared to extrinsic AD. J\u00a0Allergy Clin Immunol 132:361\u2013370","journal-title":"J Allergy Clin Immunol"},{"key":"4868_CR23","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/ijerph15061108","volume":"15","author":"W Uter","year":"2018","unstructured":"Uter\u00a0W, Werfel\u00a0T, White\u00a0IR et\u00a0al (2018) Contact allergy: a\u00a0review of current problems from a\u00a0clinical perspective. Int J Environ Res Public Health 15:1108","journal-title":"Int J Environ Res Public Health"},{"key":"4868_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jdv.13599","volume":"30","author":"A Wollenberg","year":"2016","unstructured":"Wollenberg\u00a0A, Oranje\u00a0A, Deleuran\u00a0M et\u00a0al (2016) ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and pediatric patients. J\u00a0Eur Acad Dermatol Venerol 30:729\u2013747","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"4868_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger\u00a0S, Novak\u00a0N (2016) Atopic dermatitis. Lancet 387:1109\u20131122","journal-title":"Lancet"},{"key":"4868_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","volume":"138","author":"T Werfel","year":"2016","unstructured":"Werfel\u00a0T, Allam\u00a0JP, Biedermann\u00a0T et\u00a0al (2016) Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J\u00a0Allergy Clin Immunol 138:336\u2013349","journal-title":"J Allergy Clin Immunol"},{"key":"4868_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jaip.2018.01.034","volume":"6","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg\u00a0A, Ariens\u00a0L, Thurau\u00a0S et\u00a0al (2018) Conjunctivitis occuring in atopic dermatitis patients treated with dupilumab\u2014clinical characteristics and treatment. J\u00a0Allergy Clin Immunol Pract 6:1178\u20131780","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4868_CR28","first-page":"1085","volume":"18","author":"M Worm","year":"2020","unstructured":"Worm\u00a0M, Francuzik\u00a0W, Kraft\u00a0M, Alexiou\u00a0A (2020) Modern therapies in atopic dermatitis: biologics and small molecule drugs. J\u00a0Dtsch Dermatol Ges 18:1085\u20131093","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"4868_CR29","unstructured":"Augustin M, v. Werfel T, Kiedrowski R https:\/\/www.teledermatologikum.de\/wp-content\/uploads\/AtopiTool-Checkliste-AM-Therapie-Neurodermitis.pdf. Zugegriffen: 27. Dez. 2020"},{"key":"4868_CR30","unstructured":"Fachinformation Dupixent\u00ae, Sanofi, 2021, Stand Januar"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04868-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04868-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04868-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T15:03:23Z","timestamp":1637766203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04868-4"}},"subtitle":["Eine retrospektive Kohortenanalyse aus der dermatologischen Praxis"],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4868"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04868-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"6 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Jahn hat Vortragshonorare, Reiseunterst\u00fctzungen und Beraterhonorare u.\u202fa. von Sanofi, AbbVie, Almirall, Leo, Janssen erhalten. J.\u00a0F\u00f6hr, E.\u00a0Diamanti und M.\u00a0Herbst geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine Studie an Menschen und Tieren. Es wurden retrospektiv klinische Daten erhoben, die im Praxisalltag zur Dokumentation erhoben wurden.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}